反应详情

(R)-tert-Butyl 1-(5-bromo-3-(quinoxaline-2-carboxamido)-1H-pyrrolo[2,3-b]pyridin-4-yl)piperidin-3-ylcarbamate (0.040 g, 0.071 mmol) was placed in DCM (3 mL) at room temperature. TFA (1 mL) was then added. The reaction was stirred at room temperature for 1 hour and concentrated to dryness to give the crude product, which was purified by reverse phase HPLC (0-50% ACN in water, Gilson system). The purified product was then dissolved in DCM (with minimal MeOH to aid solubility) and added dropwise to a stirring solution of 1M HCl in ether. The resulting solid was filtered, dried and collected to give (R)—N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)quinoxaline-2-carboxamide hydrochloride (0.007 g, 18% yield). LCMS (APCI+) m/z 466, 468 (M)+ (Method 2).

1. concentrationconcentrated to dryness
2. customto give the crude product, which
3. customwas purified by reverse phase HPLC (0-50% ACN in water, Gilson system)
4. dissolutionThe purified product was then dissolved in DCM (with minimal MeOH to aid solubility)
5. additionadded dropwise to a stirring solution of 1M HCl in ether
6. filtrationThe resulting solid was filtered
7. customdried
8. customcollected